Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human Annexin V Antibodies:
anti-Mouse (Murine) Annexin V Antibodies:
anti-Rat (Rattus) Annexin V Antibodies:
Go to our pre-filtered search.
Human Polyclonal Annexin V Primary Antibody for IHC (fro), IHC (p) - ABIN3043502
Jin, Liu, Wang, Xu, Yang, Lu, Sun, Hu: Protective effects of [Gly14]-Humanin on beta-amyloid-induced PC12 cell death by preventing mitochondrial dysfunction. in Neurochemistry international 2010
Show all 7 Pubmed References
Human Polyclonal Annexin V Primary Antibody for ICC, IHC (p) - ABIN3044315
Hu, Dong, Shi, Deng, Li, Lu: Evaluation of a novel tetra-functional branched poly(ethylene glycol) crosslinker for manufacture of crosslinked, decellularized, porcine aortic valve leaflets. in Journal of biomedical materials research. Part B, Applied biomaterials 2014
Show all 7 Pubmed References
Human Polyclonal Annexin V Primary Antibody for IP, IHC - ABIN223081
Lillis, Greenlee, Mikhailenko, Pizzo, Tenner, Strickland, Bohlson: Murine low-density lipoprotein receptor-related protein 1 (LRP) is required for phagocytosis of targets bearing LRP ligands but is not required for C1q-triggered enhancement of phagocytosis. in Journal of immunology (Baltimore, Md. : 1950) 2008
Show all 5 Pubmed References
Human Monoclonal Annexin V Primary Antibody for IF, IHC (p) - ABIN559879
Shui, Hsia, Chen, Chang, Wang: Proteomics and bioinformatics analysis of lovastatin-induced differentiation in ARO cells. in Journal of proteomics 2012
Show all 3 Pubmed References
Human Polyclonal Annexin V Primary Antibody for IHC (fro), IP - ABIN549073
Zandbergen, Sharma, Gupta, Verjans, van den Borne, Pokharel, van Brakel, Duijvestijn, van Rooijen, Maessen, Reutelingsperger, Pinto, Narula, Hofstra: Macrophage depletion in hypertensive rats accelerates development of cardiomyopathy. in Journal of cardiovascular pharmacology and therapeutics 2009
Show all 2 Pubmed References
Human Polyclonal Annexin V Primary Antibody for IHC, IHC (p) - ABIN5563573
Gelman, Nguyen: Synaptic proteins linked to HIV-1 infection and immunoproteasome induction: proteomic analysis of human synaptosomes. in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 2010
Show all 2 Pubmed References
Human Monoclonal Annexin V Primary Antibody for FACS - ABIN2477447
Gerke, Moss: Annexins: from structure to function. in Physiological reviews 2002
Human Polyclonal Annexin V Primary Antibody for ELISA, WB - ABIN2477449
Moss, Morgan: The annexins. in Genome biology 2004
Study identified an alternative means of supplementing anticoagulation, through elevated ANXA5 expression. Micromolar Zn2+ stimulated ANXA5 expression in cell culture directly and alleviated RPL in AnxA5 genetically deficient mice, without notable toxicity effects.
Obstetric complication-associated ANXA5 promoter polymorphisms may affect gene expression via DNA secondary structures.
AnxA5 2D-network mediates E-cadherin mobility in the plasmalemma that triggers human trophoblasts aggregation and thereby cell fusion.
Caspase-3 and -8 and annexin V may serve as diagnostic markers in Ovarian cancer , also explained that the decrement in control of the S phase in the cell cycle may considered one of the significant factors in the development of ovarian tumors
When ANXA5 expression increased, cell proliferation was inhibited by regulating the expression of bcl-2 and bax while cell metastasis was suppressed by regulating E-cadherin and MMP-9 expression.
Maternal carriers of the ANXA5 M2 haplotype has greater risk of developing placenta-mediated pregnancy complications, such as preeclampsia and intrauterine growth restriction.
The domain IV-truncated form of anxA5 is impaired in binding phosphatidylserine liposome and apoptotic cells, and anticoagulation activity.
increase in VEGF and Apelin, and decrease in Annexin A5 supports roles of hemo-dynamic alterations in fetoplacental circulation and structural alterations in uteroplacental bed occurring in preeclampsia.
In patients with colon cancer, annexin A5 expression in cancer tissues is related to lymph node metastasis and tumor grade. Serum level of annexin A5 is related to annexin A5 expression in cancer tissues.
annexin A5 anticoagulant has a role in adverse outcomes in antiphospholipid antibody positive patients with thrombosis or pregnancy complications
There was no significant difference in circulating ANXA5 levels between subjects of the non-pregnant, RPL and parous groups (median, 0.25 ng/ml vs. 0.21 ng/ml vs. 0.01 ng/ml, p = 0.14) (Fig. 1A ). Similarly, no significant differences in circulating ANXA5 levels were observed across these three clinical subgroups among M2-carriers or non-carriers, respectively.
Serum annexin A5 level was not altered in pre-eclampsia.
Annexin A5 was proposed to use in detection of apoptosis. associated with the Breast Cancer. Upregulation of the AA5 protein is detected in Pleomorphic Adenoma of the Parotid Gland.
Physiological function of ANXA5 as an embryonic anticoagulant that appears deficient in contiguous specter of thrombophilia-related pregnancy complications culminating more frequently in miscarriage in a maternal M2 carrier background.
This study confirmed the proposed role of M2/ANXA5 as embryonic, genetically associated thrombophilia predisposition factor for early recurrent pregnancy loss among ethnic Malay of Malaysia.
Circulating anxA5 levels are associated with carotid intima-media thickness but not coronary plaque composition in high-risk patients with diabetes mellitus.
Results showed that ANXA5 rs1050606 was significantly associated with left ventricular hypertrophy in Chinese endogenous hypertension patients.
Moreover, mechanism study exhibited that Annexin A5 could activate PI3K/Akt/mTOR signaling pathway, promote epithelial-mesenchymal transition (EMT) and the expression of MMP2 and MMP9. Annexin A5 may be a potential prognostic biomarker in RCC and promotes proliferation, migration and invasion of RCC cells via activating PI3K/Akt/mTOR signaling pathway and regulating EMT process and MMP expression.
human myotubes rendered deficient for Annexin-A5 (AnxA5) suffer from a severe defect in membrane resealing.
This study functionally characterized allelic variants in the ANXA5 promoter, both alone and in combinations, and the results suggest that combinations of several individual variants contribute to modulate the ANXA5 transcriptional activity, most likely through binding of nuclear factors.
Results show that despite its high levels in stereocilia, ANXA5 does not appear to play a unique functional role for the auditory and vestibular systems.
Eight-week-old ApoE-/-mice were fed a western diet while being administered AnxA5 or control (M1234) for a total of 6 weeks. AnxA5 administration reduced plaque size in the aortic root as well as the aortic arch by 36% and 55% respectively
Anxa5 mediates the in vitro malignant behaviours of murine hepatocarcinoma Hca-F cells via ERK2/c-Jun/p-c-Jun(Ser73) and ERK2/E-cadherin pathways.
findings suggest that GnRH is necessary for constitutive ANXA5 expression in the pituitary gland, not only in gonadotropes but also in other pituitary gland cell types
As a potential indicator for malignancy and lymphatic metastasis, ANXA5 overexpression increases in vitro migration and invasion of Hca-P cell, promotes in vivo malignancy, LNM rate and level of Hca-P-transplanted mice.
These data suggest that AnxA2 and AnxA5 can influence bone formation via regulation of osteoprogenitor proliferation, differentiation, and responsiveness to cytokines in addition to their well-studied function in matrix vesicles
annexin A5 may play a crucial role in cisplatin-induced toxicity by mediating the mitochondrial apoptotic pathway via the induction and oligomerization of VDAC.
The decrease of miR-1 and increase of AnxA5 appear as important modulators of NCX1 expression and activity during heart failure.
double and opposite role of annexin A5 in regulating the endocytic and autophagic pathways and the fusion of autophagosomes with lysosomes and endosomes
Hence, the presence of maternal Anxa5 minimises the risk of thrombosis in the placental circulation and reduces the risk of foetal loss.
Annexins and collagen X may rather fulfill functions in growth plate cartilage not directly linked to the mineralization process.
AnV blocked phosphatidylserine, enhanced T cell mediated tumor immunity, and inhibited tumor growth.
inhibited efferocytosis with annexin V worsened elastase-induced pulmonary emphysema in mice, which was, at least partly, attributed to a lack of phenotypic change in macrophages toward anti-inflammatory one.
AnxA5 participates in the membrane repair process.
These results indicate that annexins A5 and A6 may not represent the essential annexins that promote mineralization in vivo.
Mice lacking annexin A5 are viable, are fertile, and reveal no significant alterations in the development of skeletal elements nor the in vitro calcification properties of isolated chondrocytes.
anxA5 down-regulates surface-expressed tissue factor by activating the novel portal of cell entry
Perivascular cells expressing annexin A5 define a novel mesenchymal stem cell-like population with the capacity to differentiate into multiple mesenchymal lineages.
From the experiments presented above, we conclude that AxV influences the clearance of several PS-exposing particles such as viruses, dying, and dead cells.
The protein encoded by this gene belongs to the annexin family of calcium-dependent phospholipid binding proteins some of which have been implicated in membrane-related events along exocytotic and endocytotic pathways. Annexin 5 is a phospholipase A2 and protein kinase C inhibitory protein with calcium channel activity and a potential role in cellular signal transduction, inflammation, growth and differentiation. Annexin 5 has also been described as placental anticoagulant protein I, vascular anticoagulant-alpha, endonexin II, lipocortin V, placental protein 4 and anchorin CII. The gene spans 29 kb containing 13 exons, and encodes a single transcript of approximately 1.6 kb and a protein product with a molecular weight of about 35 kDa.
, annexin A5
, Annexin A5
, annexin A5-like
, anchorin CII
, annexin V
, calphobindin I
, endonexin II
, lipocortin V
, placental anticoagulant protein 4
, placental anticoagulant protein I
, thromboplastin inhibitor
, vascular anticoagulant-alpha
, Annexin V
, annexin V (endonexin II)